Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Version N°: 1.0 Issue Date:

ARF No: CBE/ARF/0004

PART A: To be completed by th	e Receiver (a separa	te form must be	e completed fo	r each sampl	e type)		
A1. Details of Sample/Specimen	n						
Type/ID: (eg primary cell, cell line, tiss body fluid, excreta, biological agent)	FIOZEII FBIV	Frozen PBMC aliquots				⊠Human □Animal	
Format / Quantity: (eg vials, slides,	etc) * cryovials	* cryovials					
Tissue site/Organ source:	PBMCs	PBMCs			□N/A		
Batch Nº:	015	015					
Is the sample/specimen conside If No, go to section A2.	/laterial under th	aterial under the Human Tissue Act (HTA)?			⊠Yes □No		
Is the material obtained from ar	n HTA licenced Tissue	Bank with REC	approval for ge	eneric researd	ch use?	⊠ Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval? ☐Yes ☒ ☐					. □Yes ⊠No		
Is the material licensable under	ource below:				⊠Yes □No		
☐HTA licensed organisation ☒	Commercial Supplier	r □ Imported (f	from outside E	ngland, Wales	or N.Ireland)	K .	
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°:			Assigned Unique ID (Procuro): S00144415			
If Yes, provide Project Ref N°: J15105							
If Yes, provide the name of the I	PI: Rob Thoma	S		*	e		
A2. Details of Receipt							
Date/Time of receipt	Date	18/06/2019		Time:	10.30		
ID of Receiver	Name:	Ben Diffey		Dept:	Centre for Biological Engineering		
ID of Supplier/Provider	Name:	Axol Bioscience Ltd		Country:	UK		
PART B: To be completed by the	e Receiver						
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number:154				
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describe action taken				
Quantity received correct?		⊠Yes □No	If No, describe action taken				
Labelling correct and legible?		⊠Yes □No	If No, describe action taken				
C of A or equivaler Is the relevant documentation quality		nt evidence of	⊠Yes □No □N/A		4 5		
attached to this form?	Agreements to ena material eg MTA, S		□Yes □No ⊠N/A				
If No, add reference or details to ensure traceability	Details/evidence/a consent	issurance of	rance of		*		
	Other (describe)		□Yes □No ⊠N/A				

Temporary storage - Quarantine location (as applicable)	Building/Room	281		
	Storage Unit ID			
	Within storage unit location ID	Bank 7, Rac	45, Box A 25	
	Date/Time of quarantine	:		
Submitted by:	Signature	2/1g		
PART C: To be completed by the c	departmental Quality Manage	r . 19		
C1. Quality Assurance Checks				
Has the sample/specimen been sc	□Yes □No □N/A			
Has the donor been screened for i	□Yes □No □N/A			
Has the sample/specimen been sc	□Yes □No □N/A			
Is there evidence that the supplier standards or other recognised cert	□Yes □No □N/A			
For HTA licensable material, is the storage and use of the material un	□Yes □No □N/A			
Is there sufficient evidence to supp	□Yes □No □N/A			
C2. Approval for release from qua	arantine	The Property of the Control of the C		
Can the material be released from released for processing?	quarantine and transferred to	designated storage area or	□Yes □No	
	☐ Accept as i	is, but with extra controls		
If No. was ide recommendations f	specified rea	reprocess to meet the uirements		
If No, provide recommendations for of the material and the results of a	any action Test to me	et specified requirements		
relating to non-conforming materi		supplier/provider		
	□Disposal			
	Building/Roo	m	CDE	
	Storage Unit	ID		
If Yes, provide details of storage lo applicable)	within storage	ge unit location ID	Bank 1, RS, BOX A 20	
	Database Ref	ference		
			12/11	
27 2022 (1942)	Date/Time of	f transfer	18/8/19	